Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-Term Efficacy of MK0869 in Major Depressive Disorder
NCT00048594Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Jan 2002
- Primary completion
- Dec 2003
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in major depressive disorder (MDD) comparing MK0869 with Placebo (2 arms). Primary endpoints: Hamilton Depression Rating Scale (17-item) at 10 weeks and Time to relapse of depression. Started Jan 2002; status: completed.
02
Drugs
aprepitant
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT00048594.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00048594.